|
 |
|||||||||||||||||||
|
|||||||||||||||||||
|
|||||||||||||||||||
 |
 |
|
|
 -Treated Patients
a Dipartimento di Clinica e Terapia Medica, Section of Rheumatology, Sapienza Università di Roma, Policlinico Umberto I, Roma, Italy
Key Words: autoantibodies • human antichimeric antibodies • HACA • infliximab • rheumatic inflammatory disorders
Address for correspondence: Prof. Guido Valesini, Dipartimento di Clinica e Terapia Medica, Sapienza Università di Roma, viale del Policlinico 155, 00161 Roma, Italy. Voice: +39-06-49974631; fax: +39-06-49974633. guido.valesini{at}uniroma1.it
Targeting tumor necrosis factor alpha (TNF-
 ) has offered an additional therapeutic strategy against several rheumatic inflammatory disorders. The current use of TNF- inhibitors allows physicians who manage these diseases and patients themselves to testify to an extraordinary efficacy, even though caution for possible adverse events must be maintained. Among these, the occurrence of autoimmune phenomena, encompassing new autoantibody formation and triggering of clinical manifestations, continues to be noted in published reports. Here, we review the current knowledge regarding the autoimmune phenomena linked to anti-TNF- therapy in patients with rheumatic inflammatory disorders.
|
 |
 |
